Literature DB >> 10506647

CpG DNA as mucosal adjuvant.

M J McCluskie1, H L Davis.   

Abstract

We have previously found synthetic oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs to be a potent adjuvant to protein administered by intramuscular injection or intranasal inhalation to BALB/c mice. Herein we have further evaluated the potential of CpG ODN as a mucosal adjuvant to purified hepatitis B surface antigen (HBsAg) when administered alone or with cholera toxin (CT). CpG ODN and CT both augmented systemic (humoral and cellular) and mucosal immune responses against HBsAg, and these could be further enhanced with higher doses of adjuvant or boosting. Overall, antibody isotypes with CT alone were predominantly IgG1 (Th2-like) whereas they were predominantly IgG2a (Th1-like) with CpG ODN alone or in combination with CT. Results from this study indicate that stimulatory CpG ODN are promising new adjuvants for mucosal vaccination strategies, whether used alone or in combination with other mucosal adjuvants.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506647     DOI: 10.1016/s0264-410x(99)00194-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells.

Authors:  Anne-Sophie Beignon; Jean-Paul Briand; Sylviane Muller; Charalambos D Partidos
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs.

Authors:  Valeria Alcon; Maria Baca-Estrada; Marco Vega-Lopez; Philip Willson; Lorne A Babiuk; Praveen Kumar; Rolf Hecker; Marianna Foldvari
Journal:  AAPS J       Date:  2005-10-14       Impact factor: 4.009

4.  Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization.

Authors:  Haibo Li; Jinyong Zhang; Yafei He; Bin Li; Li Chen; Weiwei Huang; Quanming Zou; Chao Wu
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

5.  A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.

Authors:  Catpagavalli Asokanathan; Michael Corbel; Dorothy Xing
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

Review 6.  Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly.

Authors:  Kohtaro Fujihashi; Shintaro Sato; Hiroshi Kiyono
Journal:  Exp Gerontol       Date:  2014-01-16       Impact factor: 4.032

7.  Intranasal immunization with autolysin (LytA) in mice model induced protection against five prevalent Streptococcus pneumoniae serotypes in China.

Authors:  Zhu Qing Yuan; Zhi Yue Lv; Hui Quan Gan; Mo Xian; Kou Xing Zhang; Jing Ying Mai; Xin Bing Yu; Zhong Dao Wu
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

8.  Intranasal CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and -independent manner.

Authors:  Hemanth Ramaprakash; Cory M Hogaboam
Journal:  Int Arch Allergy Immunol       Date:  2009-12-16       Impact factor: 2.749

9.  Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Authors:  Sang-Moo Kang; Lizheng Guo; Qizhi Yao; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity.

Authors:  Tatsuya Fukuiwa; Shinichi Sekine; Ryoki Kobayashi; Hideaki Suzuki; Kosuke Kataoka; Rebekah S Gilbert; Yuichi Kurono; Prosper N Boyaka; Arthur M Krieg; Jerry R McGhee; Kohtaro Fujihashi
Journal:  Vaccine       Date:  2008-07-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.